The clinical development will initially focus on non-small cell lung cancer (NSCLC) and pancreatic cancer.
Here you will find a range of important information about Cantargia for investors and other parties interested in our business.
Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.
Compared to similar treatments, Cantargias candidate CAN04 seems to offer a broader variety of treatment mechanisms towards the cancer".
We estimate that the company has a good chance to reach their goal considering CAN04's unique target molecule and promising basic research".
Watch the animated video
Cantargia AB (“Cantargia”) today announced that the company has received an Intention to Grant notice from the European Patent Office (“EPO”) for its patent application f...
Cantargia AB’s (”Cantargia”) year-end report for the year 2016 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.
Cantargia AB’s (“Cantargia”) CEO, Göran Forsberg, will be giving a presentation of the company at the Biotech Showcase conference in San Francisco, USA on 9 January at 4 ...